Detalles de la búsqueda
1.
Baby food pouches and Baby-Led Weaning: Associations with energy intake, eating behaviour and infant weight status.
Appetite
; 192: 107121, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37972656
2.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
AIDS Res Ther
; 16(1): 23, 2019 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31464642
3.
Baby Food Pouches, Baby-Led Weaning, and Iron Status in New Zealand Infants: An Observational Study.
Nutrients
; 16(10)2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38794732
4.
Adherence to Infant Feeding Guidelines in the First Foods New Zealand Study.
Nutrients
; 15(21)2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37960303
5.
Nutritional Implications of Baby-Led Weaning and Baby Food Pouches as Novel Methods of Infant Feeding: Protocol for an Observational Study.
JMIR Res Protoc
; 10(4): e29048, 2021 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33881411
6.
Dietary Choices of New Zealand Women during Pregnancy and Lactation.
Nutrients
; 12(9)2020 Sep 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32899261
7.
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection.
HIV Res Clin Pract
; 21(2-3): 83-89, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32715952
8.
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
HIV Res Clin Pract
; 21(6): 151-167, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528318
9.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
AIDS Res Hum Retroviruses
; 36(1): 48-57, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31516033
10.
Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV.
Curr Med Res Opin
; 35(1): 63-71, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30173561
11.
Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Clin Pharmacol Drug Dev
; 8(4): 541-548, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30508308
12.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
HIV Res Clin Pract
; 20(1): 24-33, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31303147
13.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Antiviral Res
; 170: 104543, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31279073
14.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Eur J Neurosci
; 28(1): 20-9, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18662331
15.
Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.
Infect Dis Ther
; 7(1): 147-159, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29335895
16.
Prevalence of Darunavir Resistance in the United States from 2010 to 2017.
AIDS Res Hum Retroviruses
; 34(12): 1036-1043, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30148406
17.
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 199-210, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29992490
18.
Correction to: Evaluation of Cardiovascular Disease Risk in HIV1-Infected Patients Treated with Darunavir.
Drugs R D
; 18(3): 249-250, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30079430
19.
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
AIDS Rev
; 19(1): 16-23, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28182610
20.
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
Rev Recent Clin Trials
; 12(3): 174-181, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28403798